Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 42.04%
- Healthy long term growth as Net Sales has grown by an annual rate of 38.61% and Operating profit at 52.95%
- Company has very low debt and has enough cash to service the debt requirements
2
With ROCE of 31.39%, it has a very attractive valuation with a 2.20 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
JPY 28,178 Million (Small Cap)
10.00
NA
0.00%
0.29
3.11%
2.75
Revenue and Profits:
Net Sales:
16,960 Million
(Quarterly Results - Apr 2025)
Net Profit:
-1,352 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-33.85%
0%
-33.85%
6 Months
-27.02%
0%
-27.02%
1 Year
-28.09%
0%
-28.09%
2 Years
-42.11%
0%
-42.11%
3 Years
-54.45%
0%
-54.45%
4 Years
-68.11%
0%
-68.11%
5 Years
-74.95%
0%
-74.95%
Pharma Foods International Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
38.61%
EBIT Growth (5y)
52.95%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
1.10
Net Debt to Equity (avg)
0.11
Sales to Capital Employed (avg)
2.37
Tax Ratio
85.60%
Dividend Payout Ratio
22.18%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
39.70%
ROE (avg)
35.86%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
2.34
EV to EBIT
7.02
EV to EBITDA
5.71
EV to Capital Employed
2.20
EV to Sales
0.49
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
31.39%
ROE (Latest)
22.89%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ
Apr'25
Jan'25
Change(%)
Net Sales
16,960.00
15,261.00
11.13%
Operating Profit (PBDIT) excl Other Income
-640.00
-69.00
-827.54%
Interest
27.00
17.00
58.82%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1,352.00
-131.00
-932.06%
Operating Profit Margin (Excl OI)
-49.60%
-17.00%
-3.26%
USD in Million.
Net Sales
QoQ Growth in quarter ended Apr 2025 is 11.13% vs 4.56% in Jan 2025
Consolidated Net Profit
QoQ Growth in quarter ended Apr 2025 is -932.06% vs -136.39% in Jan 2025
Annual Results Snapshot (Consolidated) - Jul'24
Jul'24
Jul'23
Change(%)
Net Sales
62,147.00
68,572.00
-9.37%
Operating Profit (PBDIT) excl Other Income
6,021.00
4,156.00
44.87%
Interest
62.00
48.00
29.17%
Exceptional Items
-123.00
-47.00
-161.70%
Consolidate Net Profit
3,205.00
3,080.00
4.06%
Operating Profit Margin (Excl OI)
82.30%
52.60%
2.97%
USD in Million.
Net Sales
YoY Growth in year ended Jul 2024 is -9.37% vs 13.94% in Jul 2023
Consolidated Net Profit
YoY Growth in year ended Jul 2024 is 4.06% vs 923.53% in Jul 2023
About Pharma Foods International Co., Ltd. 
Pharma Foods International Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






